Michael Treisman, MD
Internal Medicine · Florissant, MONPI 1184685455
Payments from drug & device makers
Across 296 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$527
- GSK$479
- Novo Nordisk$398
- AstraZeneca$383
- AbbVie$363
- Pfizer$319
- plus $2K from 27 others
Across 1 payment — averaging $6600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Currax Pharmaceuticals LLC$7K
What the payments were for
- Food & beverage$4,432100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 38 | $527 |
| GSK | 42 | $479 |
| Novo Nordisk | 28 | $398 |
| AstraZeneca | 21 | $383 |
| AbbVie | 21 | $363 |
| Pfizer | 27 | $319 |
| Amgen | 10 | $200 |
| Novartis | 12 | $194 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $178 |
| Sanofi-aventis U.S. LLC | 9 | $151 |
| Boehringer Ingelheim | 12 | $147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $141 |
| Abbott | 10 | $128 |
| Ironwood Pharmaceuticals, Inc | 5 | $93 |
| Sumitomo Pharma America, Inc. | 5 | $93 |
| Tris Pharma Inc | 4 | $76 |
| Johnson & Johnson | 3 | $65 |
| Astellas Pharma US Inc | 4 | $60 |
| Bayer | 3 | $53 |
| Dexcom, Inc. | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Amarin Pharma, Inc. | 3 | $41 |
| Merck | 3 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Shire North American Group Inc | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Medtronic | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Exact Sciences | 1 | $14 |
| Insulet Corporation | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$4,432 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 172 | $172,162 |
| OzempicSemaglutide | 77 | $121,140 |
| MounjaroTirzepatide | 98 | $113,605 |
| JardianceEmpagliflozin | 95 | $97,395 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $59,214 |
| MyrbetriqMirabegron | 43 | $44,862 |
| NeurontinGabapentin | 11 | $44,531 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 177 | $42,695 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $39,192 |
| JanuviaSitagliptin Phosphate | 38 | $39,051 |
| TrulicityDulaglutide | 20 | $35,292 |
| FarxigaDapagliflozin Propanediol | 37 | $33,504 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $20,492 |
| GemtesaVibegron | 29 | $18,028 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $16,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $319 | $183,003196 claims |
| Lilly USA, LLCMounjaro, Trulicity | $527 | $148,897118 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta | $479 | $141,101286 claims |
| Novo NordiskOzempic | $398 | $121,14077 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $147 | $118,672124 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $383 | $62,05291 claims |
| MerckJanuvia, Janumet | $39 | $52,38052 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $44,86243 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $93 | $18,02829 claims |
| Johnson & JohnsonXarelto | $65 | $11,73011 claims |
| AbbVieSynthroid | $363 | $4,02048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Florissant
- Kim McDonaldFlorissant$206K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.